… Selective phosphodiesterase 4 (PDE4) inhibitors have been shown to reduce airway …
Roflumilast is the only PDE4 approved inhibitor for the treatment of COPD patients with chronic …

… of cAMP-hydrolysing enzyme phosphodiesterase 4D (PDE4D) in HCC … inhibition of PDE4D
with roflumilast inhibited HCC … by PDE4 inhibitors in endothelial or human airway epithelial …

… skin disorders is expected to directly affect via PDE inhibition … the selective PDE4 inhibitor
roflumilast is an approved drug … effect of PDE inhibition on the highly inflamed airway tissue in …

… -specific PDE inhibitors and dual-substrate PDE inhibitors have … Roflumilast-mediated PDE4
inhibition increased the mRNA and … the role of PDE inhibitors in other CNS disorders do not …

… for their inhibitory properties against phosphodiesterases. … (IBMX) inhibited virtually all
phosphodiesterases with the … 5) have become first-line therapy for erectile dysfunction as …

… PDE1C, a Ca 2+ /calmodulin-stimulated PDE, contributed to … -selective inhibitors—such as
rolipram, roflumilast, apremilast… diseases, including inflammatory airway diseases, psoriatic …

… the extravascular compartment of inflamed lungs is a key hallmark … Ribociclib (10 μM) had
no effect on peak [Ca 2+ ] i but … Selective PDE4 inhibitors, such as roflumilast and apremilast, …

… Rall discovered PDE and theophylline as a PDE inhibitor [1]. … Ca2+ signals, commonly
referred to as intracellular Ca2+ … of roflumilast, a selective PDE4 inhibitor, and pumafentrine, a …

… the progression of the disease process in the lungs [158]. … The second generation of PDE4
inhibitors such as roflumilast … The beneficial effects of PDE inhibitors on cardiovascular co-…